✦ LIBER ✦

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

✍ Scribed by Tomihiko Yasufuku; Katsumi Shigemura; Osamu Matsumoto; Soichi Arakawa; Masato Fujisawa

Publisher: Springer
Year: 2010
Tongue: English
Weight: 168 KB
Volume: 16
Category: Article
ISSN: 1341-321X
DOI: 10.1007/s10156-010-0047-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monthly paclitaxel and carboplatin with

Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer

✍ Takehiko Segawa; Toshiyuki Kamoto; Hidefumi Kinoshita; Yasuharu Kunishima; Koji 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 378 KB

Pilot phase II study of weekly chemother

Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer

✍ Kiyoshi Mori; Yukari Kamiyama; Tetsuro Kondo; Yasuhiko Kano; Tetsuro Kodama 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 192 KB

Results from a pilot Phase I trial of ge

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

✍ George Wilding; Patrick Soulie; Donald Trump; Ashis Das-Gupta; Eric Small 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

First- and second-line chemotherapy with

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer : Does sequence matter?

✍ Jorg Michels; Trina Montemurro; Nevin Murray; Christian Kollmannsberger; Kim Ngu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

A Phase II study of estramustine, doceta

A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813

✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,